Pulmatrix (NASDAQ:PULM) Posts Earnings Results, Beats Expectations By $1.71 EPS

Pulmatrix (NASDAQ:PULM) posted its quarterly earnings data on Thursday. The biotechnology company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.00) by $1.71, FiscalAI reports.

Pulmatrix Trading Down 5.6%

Shares of NASDAQ:PULM traded down $0.09 on Thursday, reaching $1.51. 20,613 shares of the company traded hands, compared to its average volume of 10,308. The stock has a market capitalization of $5.51 million, a P/E ratio of -1.23 and a beta of 1.91. The business’s 50-day simple moving average is $1.61 and its 200 day simple moving average is $1.76. Pulmatrix has a 52 week low of $1.16 and a 52 week high of $5.50.

Analysts Set New Price Targets

Separately, Weiss Ratings upgraded Pulmatrix from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, July 30th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company presently has an average rating of “Sell”.

Institutional Trading of Pulmatrix

A hedge fund recently bought a new stake in Pulmatrix stock. Dimensional Fund Advisors LP bought a new position in Pulmatrix, Inc. (NASDAQ:PULM) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 10,780 shares of the biotechnology company’s stock, valued at approximately $52,000. Dimensional Fund Advisors LP owned 0.30% of Pulmatrix as of its most recent SEC filing. 11.84% of the stock is currently owned by institutional investors.

Pulmatrix Company Profile

Pulmatrix, Inc is a clinical-stage biopharmaceutical company dedicated to developing inhaled therapies for patients suffering from respiratory diseases. The company’s proprietary iSPERSE® dry-powder formulation platform produces fine microparticles optimized for deep-lung delivery, rapid absorption and consistent dosing, addressing challenges often encountered with traditional inhalation approaches.

Among Pulmatrix’s lead programs is PUR1900, an inhaled therapy designed to treat pulmonary fungal infections such as allergic bronchopulmonary aspergillosis (ABPA).